FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

	OMB APPROVAL										
	OMB Number:	3235-0287									
	Estimated average burden										
- 1	hours per response.	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* McKinley Kate					2. Issuer Name and Ticker or Trading Symbol Rani Therapeutics Holdings, Inc. [RANI]								ck all applic Directo	able) r	g Pers	on(s) to Issu	ner	
(Last)	,	rest) PEUTICS LLC	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 08/07/2023						2	below)	(give title F BUSIN	IESS	Other (specification) OFFICER	·	
2051 RINGWOOD AVE.				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	SE C.	A	95131										2		led by More		rting Person One Report	
(City)	(S	tate)	(Zip)		Ru	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tal	ole I - Non	-Deriv	ative	_			quired, D	<u> </u>		-		y Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Execution D		Date,	, Transaction Dispose Code (Instr. 5)			ities Acqui d Of (D) (In	red (A) or str. 3, 4 and	Securitie Beneficia	5. Amount of Securities Beneficially Owned Following		: Direct C Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership Instr. 4)		
									Code	V Am	Amount (A) or (D)		Price	Transact (Instr. 3 a				,
			Table II - [uired, Dis s, options					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	ate, Transacti Code (Ins				e s (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title an of Securit Underlyin Derivative (Instr. 3 an	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				С	Code	v	(A)	(D)	Date Exercisable	Expirati Date	ion	Title	Amount or Number of Shares		(Instr. 4)	лI(S)		
Stock Option (Right to Buy)	\$4.13	05/22/2023			A		250,000		(1)	05/21/20	033	Class A Common Stock	250,000	\$0.00	250,00	0	D	

Explanation of Responses:

1. The shares subject to the option vest 25% on May 22, 2024 and 1/48 th of the shares subject to the option vest monthly thereafter over the following three years.

Remarks:

/s/ Kate McKinley

08/08/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.